Last reviewed · How we verify
177Lu-edotreotide
177Lu-edotreotide is a radioligand therapeutic that binds to somatostatin receptor 2 (SSTR2) on neuroendocrine tumor cells and delivers targeted radiation to kill them.
177Lu-edotreotide is a radioligand therapeutic that binds to somatostatin receptor 2 (SSTR2) on neuroendocrine tumor cells and delivers targeted radiation to kill them. Used for Neuroendocrine tumors (NET) expressing somatostatin receptors, Gastroenteropancreatic neuroendocrine tumors (GEP-NET).
At a glance
| Generic name | 177Lu-edotreotide |
|---|---|
| Sponsor | Grupo Espanol de Tumores Neuroendocrinos |
| Drug class | Radioligand therapeutic; somatostatin receptor agonist |
| Target | Somatostatin receptor 2 (SSTR2) |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Edotreotide is a somatostatin analog that selectively targets somatostatin receptor 2 (SSTR2), which is overexpressed on neuroendocrine tumor cells. When labeled with the beta-emitting radionuclide lutetium-177 (177Lu), it delivers localized ionizing radiation directly to tumor tissue while sparing healthy cells, resulting in tumor cell death through DNA damage.
Approved indications
- Neuroendocrine tumors (NET) expressing somatostatin receptors
- Gastroenteropancreatic neuroendocrine tumors (GEP-NET)
Common side effects
- Nausea
- Fatigue
- Bone marrow suppression
- Kidney toxicity
- Abdominal pain
Key clinical trials
- Testing the Safety and Effectiveness of Radiation-based Treatment (Lutetium Lu 177 Dotatate) for Metastatic Prostate Cancer That Has Neuroendocrine Cells (PHASE2)
- Efficacy and Safety of Radiotherapy Compared to Everolimus in Somatostatin Receptor Positive Neuroendocrine Tumors of the Lung and Thymus. (PHASE3)
- Combination External Radiation and PRRT for Large GI Neuroendocrine Tumors. (PHASE1)
- Phase I Trial to Determine the Dose and Evaluate the PK and Safety of Lutetium Lu 177 Edotreotide Therapy in Pediatric Participants With SSTR-positive Tumors (PHASE1)
- Lutathera for the Treatment of Inoperable, Progressive Meningioma After External Beam Radiation Therapy (PHASE2)
- 177Lu-DOTATATE for the Treatment of Stage IV or Recurrent Breast Cancer (PHASE2)
- Multi-modal Characterisation of Gastroenteropancreatic Neuroendocrine Tumours (GEP-NETs) Treated With Targeted Radionuclide Therapy (TRT): Prospective Interventional Multicentre National Cohort (NA)
- Lutetium 177Lu-Edotreotide Versus Best Standard of Care in Well-differentiated Aggressive Grade-2 and Grade-3 GastroEnteroPancreatic NeuroEndocrine Tumors (GEP-NETs) - COMPOSE (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- 177Lu-edotreotide CI brief — competitive landscape report
- 177Lu-edotreotide updates RSS · CI watch RSS
- Grupo Espanol de Tumores Neuroendocrinos portfolio CI